Northstrive Biosciences, a PMGC (ELAB) company, announced the completion of a Phase I strategic research and literature synthesis for EL-22, its first-in-class oral myostatin-engineered probiotic. The analysis, conducted in collaboration with Yuva Biosciences and supported by AI-based scientific review technology from Yuva Biosciences’ MitoNova, provided valuable insights into EL-22’s proposed mechanism of action and will help guide further exploration into its potential to address critical unmet needs in muscle-wasting conditions, including GLP-1-associated atrophy and age-related sarcopenia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAB:
- Northstrive Biosciences Amends License Agreement with MOA Life
- PMGC Capital announces filing to report 5.09% stake in Alaunos Therapeutics
- ELEVAI Labs Inc. Enters New Secondment Agreement
- PMGC’s Northstrive announces signing of binding term sheet with Modulant
- Biotech Alert: Searches spiking for these stocks today